Recent Company News

• 03:40 AM ET Jun 15, 2026
  

  Goldman Sachs upgrades 4507.JP, 4519.JP

• 08:59 AM ET Jun 01, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:18 PM ET May 29, 2026
  

  FDA approves Xocova (ensitrelvir) to treat COVID-19 (¥3000.0000, 0)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May

• 02:07 AM ET May 29, 2026
  

  Shionogi & Co. receives China NPMA approval for Naldemedine for treatment of opioid-induced constipation (¥3022.0000, +25.5)

• 05:37 PM ET May 13, 2026
  

  Shionogi & Co. publishes results from SCORPIO-PEP Phase 3 study for ensitrelvir in New England Journal of Medicine (¥2978.0000, 0)

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Guidance

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Themes

• 07:15 AM ET May 13, 2026
  

  Transcript Intelligence: Shionogi & Co. Q4 Earnings Q&A

• 11:27 PM ET May 12, 2026
  

  Quick Take - Shionogi & Co. trades (6.8%) on OP miss for Q4/guide; zato fails to meet primary endpoint (¥2956.0000, -215)